Baxdrostat for uncontrolled and resistant hypertension: Clinical evidence, regulatory approval, and practical implications
Introduction: Poor blood-pressure control and treatment resistance contribute to cardiovascular and kidney complications. Excess aldosterone offers a therapeutic target. Objective: This narrative review evaluates the pharmacological profile, clinical efficacy, safety, and regulatory development of baxdrostat, an oral aldosterone synthase inhibitor designed to preserve cortisol production. Key findings: In BaxHTN, a phase 3 trial in uncontrolled or resistant hypertension, the placebo-adjusted decrease in seated systolic blood pressure at week 12 was 8.7 mmHg with 1 mg and 9.8 mmHg with 2 mg; Bax24, a phase 3 ambulatory blood-pressure trial in resistant hypertension, recorded a 14.0 mmHg placebo-adjusted decrease in 24-hour ambulatory systolic pressure with 2 mg. FigHTN, a phase 2 trial in chronic kidney disease, identified a preliminary albuminuria signal, but cardiorenal outcome studies have not yet been completed. The main recognised risks are hyperkalaemia and hyponatraemia, particularly when kidney function is impaired. The United States prescribing information states that safety and effectiveness of initiation at an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2 have not been established, and serum potassium, sodium, and eGFR require surveillance during initiation and dose adjustment. The United States Food and Drug Administration approved baxdrostat (Baxfendy) on May 15, 2026, as an add-on treatment for adults whose hypertension remains inadequately controlled. Concomitant use with a mineralocorticoid receptor antagonist has not been evaluated and should not presently be recommended. Conclusion: Comparative and long-term outcome evidence is still required, while full efficacy and safety results of the completed phase 3 BaxAsia trial in Asian populations are awaited.
Authors
- Erdiansyah Zulyadaini
- Witri Pratiwi (ORCID: https://orcid.org/0000-0001-8714-9198)
- Antonia Anna Lukito (ORCID: https://orcid.org/0000-0001-8519-8949)
- Bagus Andi Pramono
- Tuko Srimulyo
- Yogi Puji Rachmawan (ORCID: https://orcid.org/0000-0002-7976-5772)
- Wella Karolina (ORCID: https://orcid.org/0009-0007-7569-0033)
- Meity Ardiana
Institutions
- Pelita Harapan University (ID)
- University of Brawijaya (ID)
- Universitas Airlangga (ID)
- Universitas Swadaya Gunung Jati (ID)
- RSUD Prof. Dr. Saiful Anwar Malang (ID)
Publication Details
- Journal
- Eurasian Journal of Medicine and Oncology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.36922/ejmo026310392
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00